MedTrace Logo

Regional Anesthesia in Minimally Invasive Lumbar Spine Surgery

NCT05029726 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 125

Last updated 2026-02-17

No results posted yet for this study

Summary

Opioid overuse is a widespread public health crisis in the United States with increasing rates of addiction and overdose deaths from prescription opioids. Reducing the need for opiate analgesics in the post-operative setting has become a high priority in minimizing long-term opioid use in surgical patients. This study will serve to demonstrate the efficacy of the addition of regional analgesic techniques in reducing post-operative opioid requirements in patients undergoing common lumbar spinal surgical procedures.

Conditions

  • Lumbar Spinal Stenosis
  • Lumbar Disc Herniation
  • Lumbar Spondylolisthesis
  • Lumbar Spondylosis
  • Lumbar Radiculopathy
  • Lumbar Spine Instability
  • Synovial Cyst
  • Degenerative Disc Disease
  • Degenerative Spondylolisthesis
  • Degenerative Intervertebral Discs

Interventions

DRUG

Bupivacaine-Epinephrine 0.25%-1:200,000 Injectable Solution plus clonidine

Bupivacaine-Epinephrine 0.25%-1:200,000 plus clonidine 50 micrograms in 30cc syringes administered as ESPB

DRUG

normal saline

normal saline in 30cc syringes administered using ESPB technique

Sponsors & Collaborators

  • John O'Toole

    lead OTHER

Principal Investigators

  • John O'Toole, MD · Rush University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-01
Primary Completion
2027-02-01
Completion
2027-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05029726 on ClinicalTrials.gov